Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cfMSCs for Immune-related Disorders
NCT03123458Phase 1Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of clonal fetal mesenchymal stem cells in immune-related disorder, graft-versus-host disease (GVHD) and tissue damage, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Treatment-related adverse events at 1 month. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
clonal fetal mesenchymal stem cells
03
Conditions
immune-related disordergraft-versus-host disease (GVHD)tissue damage
Beyond the preview
Go deeper on NCT03123458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123458.